e-learning
resources
London 2016
Tuesday, 06.09.2016
Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Francisco Sanz Herrero (Quart de Poblet (Valencia), Spain), Francisco Sanz Herrero, Estrella Fernández-Fabrellas, Eusebi Chiner, María Luisa Briones, Ruben Lera, María Carmen Aguar, Ángela Cervera, José Blanquer
Source:
International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Session:
Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Session type:
Oral Presentation
Number:
3327
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Francisco Sanz Herrero (Quart de Poblet (Valencia), Spain), Francisco Sanz Herrero, Estrella Fernández-Fabrellas, Eusebi Chiner, María Luisa Briones, Ruben Lera, María Carmen Aguar, Ángela Cervera, José Blanquer. Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia. Eur Respir J 2016; 48: Suppl. 60, 3327
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Fluoroquinolone
versus
β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 33-39
Year: 2007
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP)
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Antibiotic treatment for nosocomial pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211
Year: 2004
Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
Treatment of nosocomial pneumonia with piperacillin-tazobactam
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016
Year: 2017
Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia?
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept